Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1625
This examiner grants 58% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17440591 | COMPOSITIONS AND METHODS FOR TREATING CUSHING'S DISEASE | Non-Final OA | The Regents of the University of California |
| 17632330 | KIF18A INHIBITORS | Final Rejection | AMGEN INC. |
| 17835261 | BRAF INHIBITORS AS PARADOX BREAKERS | Non-Final OA | Hoffmann-La Roche Inc. |
| 17785585 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | Non-Final OA | BRISTOL-MYERS SQUIBB COMPANY |
| 17763445 | METHODS AND COMPOSITIONS FOR TREATING SICKLE CELL DISEASE AND THALASSEMIA | Non-Final OA | THE UNIVERSITY OF CHICAGO |
| 17604689 | COMPOUNDS WITH ANTI-TUMOR ACTIVITY AGAINST CANCER CELLS BEARING TYROSINE KINASE INHIBITOR RESISTANT EGFR MUTATIONS | Final Rejection | Board of Regents, The University of Texas System |
| 17494110 | COMPOUNDS THAT INDUCE FERROPTIC CELL DEATH | Non-Final OA | The Board of Trustees of the University of Illinois |
| 18010690 | SPHINGOSINE-1-PHOSPHATE RECEPTOR 1 AGONIST AND LIPOSOMAL FORMULATIONS THEREOF | Non-Final OA | The Penn State Research Foundation |
| 17599188 | METHODS AND COMPOSITIONS RELATING TO TREATMENT OF CANCER | Non-Final OA | The Penn State Research Foundation |
| 18012999 | N-(3-HYDROXYPYRIDINE-2-CARBONYL)GLYCINE-BASED ANTITUMOR DRUG SENSITIZER AND APPLICATION THEREOF | Non-Final OA | ZHEJIANG UNIVERSITY |
| 17777571 | NOVEL COMPOUNDS FOR THE DIAGNOSIS, TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH THE AGGREGATION OF ALPHA-SYNUCLEIN | Final Rejection | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. |
| 17798143 | USE OF BMP INHIBITORS IN THE TREATMENT OF MOLAR PREGNANCY | Final Rejection | BOGAZICI UNIVERSITESI |
| 18286634 | COMPOSITION FOR STIMULATING IMMUNE CELL METABOLISM | Non-Final OA | SUNTORY HOLDINGS LIMITED |
| 18039661 | NOVEL RIPK1 KINASE TARGETING PROTACS AND METHODS OF USE THEREOF | Non-Final OA | Baylor College of Medicine |
| 17990976 | Application of microbiota-derived plasmalogens to Treatment of Colon Cancer | Non-Final OA | Jiangnan University |
| 17437724 | CANCER TREATMENT COMPRISING NALTREXONE AND A CANNABINOID | Final Rejection | LDN Pharma Limited |
| 17998117 | Method For Treating Pancreatic Cancer | Non-Final OA | Lantern Pharma Inc. |
| 18280868 | USE OF A COMPOUND CONTAINING A TRICYCLIC HETEROARYL GROUP | Non-Final OA | CSPC Ouyi Pharmaceutical Co., Ltd |
| 17521884 | METHOD OF TREATING A SKIN DISORDER WITH EGFR INHIBITOR | Final Rejection | Sol-Gel Technologies Ltd. |
| 18039985 | PYRROLE-TYPE COMPOUNDS AND USES THEREOF FOR TREATING VIRAL INFECTIONS | Non-Final OA | ENYO PHARMA |
| 17914872 | SMALL MOLECULES INDUCING THE DEGRADATION OF THE CELLULAR PRION PROTEIN | Non-Final OA | FONDAZIONE TELETHON |
| 17605369 | MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY | Final Rejection | EVOTEC INTERNATIONAL GMBH |
| 18005952 | 5-HT2A RECEPTOR INHIBITOR OR INVERSE AGONIST, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Non-Final OA | GENEORA PHARMA (SHIJIAZHUANG) CO., LTD. |
| 18014830 | COMBINED PHARMACEUTICAL PREPARATION FOR TREATING A TERMINAL NON-SMALL CELL LUNG CANCER PATIENT WITH BRAIN METASTASIS | Non-Final OA | DELTA-FLY PHARMA, INC. |
| 18010913 | ERG ONCOGENE INHIBITORS | Non-Final OA | Mallesh Pandrala |
| 17906184 | PROTEOLYSIS TARGETING CHIMERA (PROTAC) FOR DEGRADATION OF AURORA A-KINASE | Non-Final OA | Julius-Maximilians-Universitaet Wuerzburg |
| 17791283 | Heteroaryl Derivative, Preparation Method Therefor, And Use Thereof | Final Rejection | Shanghai Aryl Pharmtech Co., Ltd. |
| 17586277 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | Non-Final OA | XRad Holding Cayman Limited |
| 17630887 | ADENOSINE RECEPTOR ANTAGONIST | Non-Final OA | XIAMEN BIOTIME BIOTECHNOLOGY CO., LTD. |
| 17625415 | COMPOSITIONS AND METHODS FOR TREATING PLANT PARASITES | Final Rejection | Arizona Board Regents on Bealf of the University of Arizona |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy